Scholar Rock (NASDAQ:SRRK) Sets New 12-Month High – Should You Buy?

Scholar Rock Holding Corporation (NASDAQ:SRRK) shares reached a new 52-week high during trading on Wednesday . The company traded as high as $50.50 and last traded at $49.16, with a volume of 5327282 shares changing hands. The stock had previously closed at $43.08.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. BMO Capital Markets boosted their target price on Scholar Rock from $50.00 to $70.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 4th. Barclays increased their price target on shares of Scholar Rock from $52.00 to $53.00 and gave the company an “overweight” rating in a research note on Tuesday, March 3rd. Truist Financial boosted their price objective on shares of Scholar Rock from $44.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. HC Wainwright restated a “buy” rating and issued a $58.00 target price on shares of Scholar Rock in a report on Tuesday, March 3rd. Finally, Raymond James Financial reaffirmed a “strong-buy” rating on shares of Scholar Rock in a research report on Tuesday, March 3rd. Four investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Scholar Rock has an average rating of “Buy” and an average price target of $54.36.

Scholar Rock Trading Up 14.1%

The business has a 50-day moving average of $45.11 and a 200-day moving average of $40.62. The stock has a market capitalization of $5.65 billion, a price-to-earnings ratio of -14.33 and a beta of 0.70. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.95 and a current ratio of 6.95.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.10. During the same period last year, the company earned ($0.64) earnings per share. As a group, research analysts forecast that Scholar Rock Holding Corporation will post -2.42 EPS for the current year.

Insider Buying and Selling at Scholar Rock

In other news, insider Jing L. Marantz sold 4,157 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total transaction of $193,425.21. Following the completion of the sale, the insider owned 126,012 shares in the company, valued at approximately $5,863,338.36. This represents a 3.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Junlin Ho sold 9,580 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total value of $445,757.40. Following the transaction, the general counsel directly owned 241,545 shares in the company, valued at approximately $11,239,088.85. This represents a 3.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 207,464 shares of company stock worth $9,157,423 in the last quarter. 13.30% of the stock is currently owned by company insiders.

Institutional Trading of Scholar Rock

Hedge funds have recently added to or reduced their stakes in the stock. IFP Advisors Inc increased its holdings in shares of Scholar Rock by 294.1% in the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after purchasing an additional 450 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Scholar Rock during the fourth quarter worth $30,000. Summit Securities Group LLC acquired a new stake in shares of Scholar Rock during the fourth quarter worth $31,000. Ramirez Asset Management Inc. purchased a new position in Scholar Rock in the 3rd quarter valued at $37,000. Finally, EverSource Wealth Advisors LLC increased its stake in Scholar Rock by 151.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after buying an additional 525 shares during the period. 91.08% of the stock is owned by institutional investors and hedge funds.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).